
==== Front
World J Hepatol
WJH
World Journal of Hepatology
1948-5182
Baishideng Publishing Group Inc

39221100
jWJH.v16.i8.pg1145
10.4254/wjh.v16.i8.1145
96966
Clinical and Translational Research
Blood cell counts and nonalcoholic fatty liver disease: Evidence from Mendelian randomization analysis
Hu B et al. Blood cells and liver disease: Mendelian evidence
Hu Bin Department of Laboratory Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, China

Wan Ai-Hong Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, China

Xiang Xi-Qiao Department of Positron Emission Tomography-Computed Tomography Imaging Center, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, China

Wei Yuan-Hao Department of School of Public Health, Harbin Medical University, Harbin 150081, Heilongjiang Province, China

Chen Yi Department of Positron Emission Tomography-Computed Tomography Imaging Center, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, China

Tang Zhen Department of Positron Emission Tomography-Computed Tomography Imaging Center, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, China

Xu Chang-De Department of Positron Emission Tomography-Computed Tomography Imaging Center, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, China

Zheng Zi-Wei Department of Cardiovascular Ultrasound Medicine Center, Shanghai Eighth People's Hospital, Shanghai 200235, China

Yang Shao-Ling Department of Cardiovascular Ultrasound Medicine Center, Shanghai Eighth People's Hospital, Shanghai 200235, China

Zhao Kun Department of Positron Emission Tomography-Computed Tomography Imaging Center, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, China. zzleaning@163.com

Co-first authors: Bin Hu and Ai-Hong Wan.

Co-corresponding authors: Shao-Ling Yang and Kun Zhao.

Author contributions: Yang SL and Zhao K conceptualized and designed the research; Hu B and Wan AH wrote the original draft of the manuscript, contributed equally to this work and share first authorship; Xiang XQ and Wei YH performed the statistical analysis; Chen Y, Tang Z, Xu CD, and Zheng ZW contributed to the acquisition, analysis, or interpretation of the data. Both Yang SL and Zhao K have played important and indispensable roles in the study design, data interpretation, and manuscript preparation as the co-corresponding authors. Yang SL was instrumental in conceptualizing the study's framework, devising innovative methodologies, and overseeing the experimental design., and also obtained the funds for this research project. Zhao K excelled in leading the data analysis process, applying sophisticated statistical techniques to interpret the results. This collaboration between Yang SL and Zhao K is crucial for the publication of this manuscript and other manuscripts still in preparation.

Supported by the Shanghai Natural Science Foundation of China, No. 23ZR1447800 ; and the Fengxian District Science and Technology Commission Project, China, No. 20211838.

Corresponding author: Kun Zhao, MD, Doctor, Department of Positron Emission Tomography-Computed Tomography Imaging Center, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, No. 6600 Nanfeng Highway, Shanghai 201499, China. zzleaning@163.com

27 8 2024
27 8 2024
16 8 11451155
19 5 2024
3 7 2024
23 7 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
BACKGROUND

Previous research has highlighted correlations between blood cell counts and chronic liver disease. Nonetheless, the causal relationships remain unknown.

AIM

To evaluate the causal effect of blood cell traits on liver enzymes and nonalcoholic fatty liver disease (NAFLD) risk.

METHODS

Independent genetic variants strongly associated with blood cell traits were extracted from a genome-wide association study (GWAS) conducted by the Blood Cell Consortium. Summary-level data for liver enzymes were obtained from the United Kingdom Biobank. NAFLD data were obtained from a GWAS meta-analysis (8434 cases and 770180 controls, discovery dataset) and the Fingen GWAS (2275 cases and 372727 controls, replication dataset). This analysis was conducted using the inverse-variance weighted method, followed by various sensitivity analyses.

RESULTS

One SD increase in the genetically predicted haemoglobin concentration (HGB) was associated with a β of 0.0078 (95%CI: 0.0059-0.0096), 0.0108 (95%CI: 0.0080-0.0136), 0.0361 (95%CI: 0.0156-0.0567), and 0.0083 (95%CI: 00046-0.0121) for alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase, and gamma-glutamyl transferase, respectively. Genetically predicted haematocrit was associated with ALP (β = 0.0078, 95%CI: 0.0052-0.0104) and ALT (β = 0.0057, 95%CI: 0.0039-0.0075). Genetically determined HGB and the reticulocyte fraction of red blood cells increased the risk of NAFLD [odds ratio (OR) = 1.199, 95%CI: 1.087-1.322] and (OR = 1.157, 95%CI: 1.071-1.250). The results of the sensitivity analyses remained significant.

CONCLUSION

Novel causal blood cell traits related to liver enzymes and NAFLD development were revealed through Mendelian randomization analysis, which may facilitate the diagnosis and prevention of NAFLD.

Blood cell counts
Liver enzymes
Nonalcoholic fatty liver disease
Genome-wide association
Mendelian randomization study
Causal relationship
==== Body
pmc Core Tip: Mendelian randomization analysis revealed a novel evidence for a causal role of genetically predicted blood cell traits in liver injury and nonalcoholic fatty liver disease (NAFLD). The study found that genetically determined increases in hemoglobin concentration (HGB) and hematocrit levels were associated with elevated levels of liver enzymes. In addition, genetic determinants of HGB and reticulocyte ratio are associated with an increased risk of NAFLD. These findings may help in the diagnosis and prevention of NAFLD.

INTRODUCTION

Chronic liver disease (CLD), including nonalcoholic fatty liver disease (NAFLD), is a significant cause of mortality and liver cancer, accounting for 3.5% of all deaths worldwide[1]. The incidence of NAFLD, a chronic metabolic stress-related liver disease, is increasing, contributing to the rapid increase in the global burden of liver disease[2]. The insidious onset and complex pathogenesis of NAFLD are not fully understood, but the disease is closely associated with insulin resistance (IR), genetic predisposition, and an increased risk of developing cirrhosis, end-stage liver disease, and hepatocellular carcinoma over time[3-5]. Serum liver enzymes, including alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT), are considered important markers in the clinical assessment of liver injury, and they are associated with the risk of developing NAFLD[6,7]. Given the invasive nature of the gold standard for NAFLD biopsy and the limitations of diagnostic imaging criteria, there is a need to search for noninvasive circulating biomarkers. In addition, determining the causal relationships among diseases is the first step towards rational and individualized treatment.

Blood cell counts are quantitative clinical laboratory measures that characterize the production of haematopoietic progenitor cells, the synthesis of haemoglobin, and the clearance of mature or senescent blood cells from the circulation[8]. Considering the vital functions of blood cells in delivering tissue oxygen, managing inflammatory responses, addressing atherosclerosis, and preventing thrombosis, factors contributing to interpopulation variations in blood cell traits may significantly impact the development of CLD and contribute to health disparities among populations[9,10]. However, the limitations of these studies include potential confounding factors, reverse causality, and the inability to establish causality because of their cross-sectional or retrospective nature. Determining if blood cell counts are causally involved in the progression of NAFLD is of significant clinical importance

Mendelian randomization (MR), an emerging method, offers a novel approach to address these limitations. By utilizing single-nucleotide polymorphisms (SNPs) identified from genome-wide association studies (GWASs) as instrumental variables (IVs), MR analysis leveraging genetic variants randomly allocated at conception helps mitigate biases from confounders and reverse causation, resembling a "natural" randomized controlled trial[11]. Many powerful GWASs have identified thousands of SNPs associated with blood cell-related traits or circulating liver enzyme levels[9,12,13]. This creates an opportunity to test genetic, potentially causal relationships between blood cell traits and relevant CLD-associated traits using the MR approach.

Therefore, in this context, we conducted a two-sample bidirectional MR design and systematically assessed the potential causal relationships between blood cell counts and CLD-associated traits.

MATERIALS AND METHODS

A summary of the research methodology is depicted in Figure 1. The study is reported according to the STROBE-MR checklist guidelines (https://www.strobe-mr.org/)[14]. The summary data from the GWAS employed in this research are accessible to the public for download, and every original investigation secured written consent from the subjects involved, with endorsement from ethical review boards. An overview of the GWAS data sources used for MR analysis is shown in Table 1.

Figure 1 Mendelian randomization assumptions and study design. Mendelian randomization (MR) analysis relies on three key assumptions. Assumption 1: Genetic variants are closely associated with exposure (blood cell traits); Assumption 2: Genetic variants are not associated with any potential confounders; Assumption 3: Genetic variants are not associated with outcome (liver enzymes and nonalcoholic fatty liver disease) except via exposure. MR: Mendelian randomization; MRPRESSO: Mendelian randomization pleiotropy residual sum and outlier; RBC: Red blood cell count; HGB: Haemoglobin concentration; HCT: Haematocrit; MCH: Mean corpuscular haemoglobin; MCV: Mean corpuscular volume; MCHC: Mean corpuscular haemoglobin concentration; RDW: Red cell distribution width; WBC: White blood cell count; NEU: Neutrophil count; LYM: Lymphocyte count; MONO: Monocyte count; BASO: Basophil count; EO: Eosinophil count; PLT: Platelet count; MPV: Mean platelet volume; RET: Reticulocyte count; RET%: Reticulocyte fraction of red cells; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; AST: Aspartate aminotransferase; NAFLD: Nonalcoholic fatty liver disease. Created with BioRender.com.

Table 1 Characteristics of summary-level data used in the Mendelian randomization analysis

Phenotypes	Trait name	Unit	Sample size	No. of cases	Ethnicity	Adjustment	Ref.	
Red blood cells	RBC	per pL	563946	545203	European	Age, sex, the first 10 principal components, and cohort-specific covariates were corrected in the original GWAS	[9]	
HGB	g/dL	563946	563946	European	
HCT	%	563946	562259	European	
MCH	pg	563946	491553	European	
MCV	fL	563946	544127	European	
MCHC	g/dL	563946	491553	European	
RDW	fL	563946	531774	European	
Immature red cells	RET	pL	408112	408112	European	[10]	
RET%	%	408112	408112	European	
White blood cells	WBC	per nL	563946	562243	European	[9]	
NEU	per nL	563946	519288	European	
LYM	per nL	563946	524923	European	
MONO	per nL	563946	521594	European	
BASO	per nL	563946	474001	European	
EO	per nL	563946	474237	European	
Platelets	PLT	per nL	563946	542827	European	
MPV	fL	563946	460935	European	
Covariates	WHR	SD	694649	694649	European	BMI	[27]	
T2D	Log (OR)	933970	80154	European	Age, sex, study-specific covariates, and principal components	[28]	
Liver enzymes	ALP	SD	437438	437438	European	Age and sex and principal components of genetically inferred ancestry	[12]	
ALT	SD	437267	437267	European	
GGT	SD	437194	437194	European	
AST	SD	411048	411048	European	Age sex, BMI, and the first 12 principal components of genetic ancestry	[13]	
Chronic liver diseases	NAFLD (Ghodsian et al[15], 2020)	Log (OR)	778614	8434	European	BMI	[15]	
NAFLD (Fingen 10)	Log (OR)	375002	2275	European	Age, sex, the first 10 genetic principal components, and genotyping batch	-	
GWAS: Genome-wide association study; OR: Odds ratio; BMI: Body mass index; RBC: Red blood cell count; HGB: Haemoglobin concentration; HCT: Haematocrit; MCH: Mean corpuscular haemoglobin; MCV: Mean corpuscular volume; MCHC: Mean corpuscular haemoglobin concentration; RDW: Red cell distribution width; RET: Reticulocyte count; RET%: Reticulocyte fraction of red cells; WBC: White blood cell count; NEU: Neutrophil count; LYM: Lymphocyte count; MONO: Monocyte count; BASO: Basophil count; EO: Eosinophil count; PLT: Platelet count; MPV: Mean platelet volume; WHR: Waist-to-hip ratio; T2D: Type 2 diabetes; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; AST: Aspartate aminotransferase; NAFLD: Nonalcoholic fatty liver disease.

GWAS summary statistics of 17 blood cell count traits

Summary statistics for the 17 blood cell traits were derived from comprehensive GWASs conducted by the Blood Cell Consortium and the United Kingdom Biobank (UKB), which represents the largest GWAS on blood cell traits to date, encompassing 563085 participants of European ancestry[9,10]. In the original GWAS, meticulous efforts were made to correct for potential confounders, including age, sex, the first 10 principal components of genetic ancestry, and cohort-specific covariates, to ensure the robustness of the genetic associations identified. The specific blood cell traits analysed included 8 red blood cell traits [red blood cell count (RBC); haemoglobin concentration (HGB); haematocrit (HCT); mean corpuscular haemoglobin (MCH); mean corpuscular volume; mean corpuscular haemoglobin concentration; red cell distribution width (RDW)], 2 immature red cell traits [reticulocyte count (RET); reticulocyte fraction of red cells (RET%)], 6 white blood cell traits [white blood cell count (WBC); neutrophil count (NEU); lymphocyte count (LYM); monocyte count (MONO); basophil count (BASO); eosinophil count (EO)], and 2 platelet traits [platelet count (PLT); mean platelet volume (MPV)]. Complete summary statistics from GWASs of blood cell traits can be downloaded from the GWAS catalogue (https://www.ebi.ac.uk/gwas/).

GWAS summary statistics of liver enzymes and NAFLD

Genetic associations with ALP, ALT, and GGT were extracted from GWASs conducted by Pazoki et al[12]. We utilized data from the UKB and included 437267 individuals aged between 40 and 69 years. Study participants were identified through the United National Health Service Registers across 22 centres in the UKB between the years 2006 and 2010. The study included individuals of European ancestry, following quality measures and exclusions such as sex, high missingness, and/or heterozygosity. The summary datasets of AST were derived from a GWAS meta-analysis of 411048 individuals in the UKB (adjusted for various factors, including the age at recruitment, sex, body mass index, and the first 12 principal components of genetic ancestry)[13].

The summary level GWAS statistics for NAFLD in the primary analysis were obtained from the Ghodsian et al’s study[15], which included 8434 NAFLD cases and 770180 controls of European ancestry (discovery dataset). The study integrated data from four additional GWASs: The Electronic Medical Records and Genomics, the FinnGen consortium, the UKB, and the Estonian Biobank. NAFLD diagnosis was determined on the basis of electronic health records or hospital records for all participants. Specifically, NAFLD was defined by the use of EHR codes and the International Classification of Diseases (ICD) (ICD9: 571.5, ICD9: 571.8, ICD9: 571.9, ICD10: K75.81, ICD10: K76.0 and ICD10: K76.9). To validate our results via replication analysis and meta-analysis, we used NAFLD (2275 NAFLD cases and 375002 controls) and data from the FinnGen consortium (replication dataset), which is publicly available at the following website (https://R10.finngen.fi/).

Instrumental variable selection

We extracted all SNPs that strongly and independently predicted 17 blood cell traits at the threshold of genome-wide significance (P < 5 × 10-8). After the significant SNPs corresponding to each blood cell trait were extracted, a linkage disequilibrium (LD) evaluation was conducted utilizing the European genetic profiles from a cohort of 1000 subjects as a benchmark and excluding potential LD (with R2 < 0.001 within a 10000 kb region), palindromic structural SNPs (minor allele frequency > 0.42), and incompatible SNPs[16]. We calculated the F statistic (F = β2/SE2) for each SNP (F statistic range 29.75 to 1600.00), F > 10, suggesting the absence of weak instrumental bias[17]. In addition, we aimed to estimate the causal effects of genetically predicted liver enzymes and NAFLD on blood cell traits. We further performed reverse MR analyses. Data harmonization and MR methods were also performed as described in the forwards MR analysis. Comprehensive details regarding these exposures, outcomes, datasets, and IVs are presented in Supplementary Table 1.

MR and sensitivity analyses

Before conducting the MR analysis, SNPs directly related to the liver enzymes and NAFLD data were removed to avoid potential horizontal pleiotropy (P < 5 × 10-8). The primary analysis used inverse-variance weighted (IVW) with a random effects model[18]. In addition, a range of sensitivity analyses, such as MR-Egger[19], weighted median[20], weighted mode[21], simple mode, and penalized weighted median methods, were performed to evaluate the potential bias in the MR setting. In addition, RadialMR and MR pleiotropy residual sum and outlier (MRPRESSO, NbDistribution = 3000) were utilized to identify outliers with multiple effects across all levels for variables exhibiting significant causal links, followed by a re-evaluation of the causality estimates subsequent to the exclusion of these outliers[22,23]. Furthermore, we also performed sensitivity analyses using MR-Egger regression (assessing the presence of directional pleiotropy) to determine the robustness of the IVW results, in which a P value for the intercept < 0.05 was considered statistically significant[24]. Cochran's Q statistic checks the heterogeneity of individual causal effects, and leave-one-out analysis examines the effects of outlying and pleiotropic SNPs on causal estimates[25,26]. To control the influence of pleiotropy within this research, we proceeded to perform multivariable MR (MVMR) analyses, which accounted for the waist-to-hip ratio (WHR)[27] and type 2 diabetes (T2D)[28]. MVMR facilitates the concurrent assessment of causal relationships among various predictors and outcomes[29]. MVMR was executed employing the IVW approach as the principal technique and the Egger regression method for supplementary evaluations.

All the statistical analyses were performed using the TwoSampleMR (version 0.5.4), RadialMR (version 1.0), and MRPRESSO (version 1.0) packages in R software (version 4.2.2). The MR estimates are reported as effect sizes (β) or odds ratios (ORs) along with 95%CIs. The statistical significance threshold was defined as a P value < 5.88 × 10-4 (0.05/17 exposure × 5 outcome) after Bonferroni correction to address multiple testing issues[30]. If a P value was between 5.58 × 10-4 and 0.05, it was considered to indicate a potential causal relationship with nominal significance. For the MVMR analysis, a P value < 0.05 was considered statistically significant.

RESULTS

Causal estimates between blood cell traits and liver enzymes

Specifically, IVW MR analysis revealed a statistically significant association between genetically predicted higher RBC levels and ALP (β = 0.0043, 95%CI: 0.002-0.0065, PIVW = 1.84E-04 per 1-SD increase). Higher HGB levels were significantly associated with ALP (β = 0.0079, 95%CI: 0.0051-0.0107, PIVW = 3.07E-08), ALT (β = 0.0128, 95%CI: 0.0085-0.0170, PIVW = 4.69E-09), AST (β = 0.0713, 95%CI: 0.0395-0.1031, PIVW = 1.12E-05) and GGT (β = 0.0108, 95%CI: 00049-0.0168, PIVW = 3.73E-04; Supplementary Table 2). In addition, genetically determined higher HCT levels (per 1-SD increase) were significantly associated with the levels of ALP (β = 0.0060, 95%CI: 0.0033-0.0087, PIVW = 1.14E-05) and ALT (β = 0.0075, 95%CI: 0.0034-0.0116, PIVW = 3.05E-04). The RadialMR and MRPRESSO tests were used to identify any level of multieffect outliers and reassessed the causal effect estimates after removing outliers, and the results remained significant (Supplementary Table 3).

Another aspect, genetically determined higher circulating levels of WBC, NEU, and BASO, was associated with increased levels of ALP (β = 0.0031, 95%CI: 0.0005-0.0056, PIVW = 1.89E-02 per 1-SD increase in WBC; β = 0.0035, 95%CI: 0.0007-0.0062, PIVW = 1.25E-02 per 1-SD increase in NEU; β = 0.0041, 95%CI: 0.0004-0.0077, PIVW = 2.87E-02 per 1-SD increase in BASO; Supplementary Table 2). Genetically predicted RBC, MCH, RET, RET%, and LYW were associated with the levels of ALT (β = 0.0040, 95%CI: 0.0005-0.0075, PIVW = 2.42E-02 per 1-SD increase in RBC; β = 0.0042, 95%CI: 0.0012-0.0071, PIVW = 5.26E-03 per 1-SD increase in MCH; β = 0.0052, 95%CI: 0.0017-0.0087, PIVW = 4.00E-03 per 1-SD increase in RET; β = 0.0050, 95%CI: 0.0019-0.0080, PIVW = 1.58E-03 per 1-SD increase in RET%; β = 0.005, 95%CI: 0.0013-0.0086, PIVW = 7.88E-03 per 1-SD increase in LYM).

We detected a positive correlation between HCT levels and AST (β = 0.0452, 95%CI: 0.0162-0.0742, PIVW = 2.23E-03 per 1-SD increase in HCT). Similarly, we observed that the levels of RBC, HCT, and PLT were suggestively associated with the levels of GGT, with β values of 0.0078 (95%CI: 0.003-0.0126 PIVW = 1.35E-03), 0.0064 (95%CI: 0.001-0.0118 PIVW = 2.09E-02), and β of 0.0068 (95%CI: 0.0027-0.0109 PIVW = 1.06E-03), respectively. Interestingly, genetically predicted higher RDWs were inversely associated with the levels of ALT (β = -0.0034, 95%CI: -0.0067 to -0.0002, PIVW = 3.95E-02) and AST (β = -0.0248, 95%CI: -0.046 to -0.0035, PIVW = 2.21E-02). No significant causal associations were found between other genetically driven blood cell traits and liver enzymes.

Causal estimates between blood cell traits and the risk of NAFLD

After removing outliers, the MR results revealed that genetically predicted HGB and RET% increased the risk of NAFLD (OR = 1.199, 95%CI: 1.087-1.322, PIVW = 2.70E-04) and (OR = 1.157, 95%CI: 1.071-1.250, PIVW = 2.24E-04; Supplementary Table 4). Nevertheless, we observed a potential positive correlation between genetically elevated levels of RET and the risk of NAFLD (OR = 1.137, 95%CI: 1.051-1.229, PIVW = 1.29E-03). In addition, MR analysis suggested that a genetic predisposition to higher HGB, RET, and RET% was causally associated with an increased risk of NAFLD in both discovery, replication, and meta-analyses (Figure 2).

Figure 2 Associations of genetically predicted blood cell counts with the risk of nonalcoholic fatty liver disease in the discovery, replication, and combined datasets. OR: Odds ratio; RBC: Red blood cell count; HGB: Haemoglobin concentration; HCT: Haematocrit; MCH: Mean corpuscular haemoglobin; MCV: Mean corpuscular volume; MCHC: Mean corpuscular haemoglobin concentration; RDW: Red cell distribution width; WBC: White blood cell count; NEU: Neutrophil count; LYM: Lymphocyte count; MONO: Monocyte count; BASO: Basophil count; EO: Eosinophil count; PLT: Platelet count; MPV: Mean platelet volume; RET: Reticulocyte count; RET%: Reticulocyte fraction of red cells; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; AST: Aspartate aminotransferase; NAFLD: Nonalcoholic fatty liver disease.

Sensitivity analysis and MVMR results

No evidence of heterogeneity (Cochranes’s Q, P value > 0.05) or horizontal pleiotropy (MR-Egger intercept, P value > 0.05) was observed in the MR estimates (Supplementary Table 5). The global tests from RadialMR and MRPRESSO were utilized to identify outliers with multiple effects across all levels for associations with significant causality and to reevaluate the causality estimates after these outliers were removed. The results remained stable (Supplementary Tables 3 and 4). Additionally, a leave-one-out sensitivity analysis was conducted, successively excluding each SNP associated with risk factors and recalculating the MR outcomes for the remaining SNPs. Notably, this analysis confirmed the stability of the outcomes (Supplementary Figures 1-10). The visual representations, including scatter plots, funnel plots, forest plots, and leave-one-out plots, are shown in Supplementary Figures 1-10.

Within the MVMR framework, we adjusted for two key confounding factors (WHR and T2D). Our findings revealed that the causal relationships remained robust and consistent, notwithstanding the consideration of a range of influencing factors (Figure 3A and Supplementary Table 6). However, the associations between genetically determined HGB and GGT levels were nonsignificant (β = 0.0128, 95%CI: 0.0024-0.0233, PIVW = 1.62E-02 per 1-SD increase in HGB) (MVMR-IVW method) and (β = 0.0134, 95%CI: 0.0028-0.0238, PIVW = 1.26E-02 per 1-SD increase in HGB) (MVMR-Egger method). Importantly, most of the P values of the MVMR-Egger intercept were > 0.05, suggesting a low likelihood of pleiotropy.

Figure 3 Inverse-variance weighted–Mendelian randomization results before and after correcting for waist-to-hip ratio and type 2 diabetes using the multivariable Mendelian randomization framework. A: Blood cell counts associated liver enzyme; B: Blood cell counts associated liver enzyme. OR: Odds ratio; RBC: Red blood cell count; HGB: Haemoglobin concentration; HCT: Haematocrit; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; AST: Aspartate aminotransferase; NAFLD: Nonalcoholic fatty liver diseases; T2D: Type 2 diabetes.

The positive effects of RET (OR = 1.266, 95%CI: 1.070-1.498, PIVW = 1.29E-03, per 1-SD increase) and RET% (OR = 1.264, 95%CI: 1.165-1.371, PIVW = 1.59E-08) remained following adjustments for WHR and T2D in the multivariable MR analysis (Figure 3B and Supplementary Table 6). Furthermore, there was an inconsistency between the MVMR-Egger results and the MVMR-IVW analysis results. For example, genetically predicted HGB and the risk of NAFLD became nonsignificant (OR = 1.165, 95%CI: 0.987-1.373, PIVW = 7.03E-04, per 1-SD increase in HGB). In addition, most of the P values of the MVMR-Egger intercept were > 0.05, indicating a low likelihood of pleiotropy.

Causal estimates between liver enzymes, NAFLD, and blood cell counts

We performed reverse MR analysis on the significant results of the positive MR (after Bonferroni correction). Characteristics of the genetic variants were associated with liver enzyme levels and NAFLD (Supplementary Table 7). The IVW MR analysis revealed that ALP had significant causal effects on increases in RBC (β = 0.5365, 95%CI: 0.2636-0.8094, PIVW = 1.17E-04) and HCT (β = 0.4562, 95%CI: 0.2046-0.7077, PIVW = 3.78E-04; Supplementary Table 8). In addition, higher ALT levels were significantly associated with HGB levels (β = 0.3576, 95%CI: -0.1262 to 0.8412, PIVW = 5.83E-05). All additional methods yielded similar results, except for MR-Egger and weighted methods (Supplementary Table 8). In addition, genetic susceptibility to NAFLD risk was not associated with HGB (β = 0.2892, 95%CI: -0.0139 to 0.5923, PIVW = 3.52E-03), RET (β = 0.0014, 95%CI: -0.0731 to 0.0759, PIVW = 9.70E-01), or RET% (β = -0.0097, 95%CI: -0.0876 to 0.0683, PIVW = 8.08E-01).

DISCUSSION

In this MR study, we provided new novel evidence for the causal roles of 17 genetically predicted blood cell traits in liver injury and the development of NAFLD. We found that genetically predicted HGB and HCT were causally associated with a wide range of levels of liver injury. Elevated HGB, RET, and RET% were strong indicators of an increased risk of NAFLD. Similarly, the multivariate MR and sensitivity analyses remained significant. These findings highlight the roles of blood cell traits in the pathogenesis of NAFLD and provide new evidence for understanding the impact of abnormal liver function on blood biology, which may facilitate its diagnosis and prevention.

Blood is described as a viscous non-Newtonian fluid, with more than 95% of blood being red blood cells, thus determining its critical role in whole blood viscosity (WBV). WBV is a crucial physiological and pathological marker that often increases with the onset of chronic conditions such as inflammation, aging, and NAFLD[31-33]. Understanding the pivotal role of WBV as a physiological and pathological marker provides valuable insights into the interconnected mechanisms at play. Prior research has underscored the robust correlation between elevated RBC levels and various health conditions, such as IR, metabolic syndrome (Mets), and NAFLD, and emphasized the significance of hematological parameters in assessing metabolic health[34-36]. Moreover, in the context of NAFLD, elevated RBC counts have been identified as an independent predictor of disease progression, suggesting their potential utility as a diagnostic biomarker[37]. The widely accepted "multiple parallel hits" hypothesis offers a comprehensive understanding of NAFLD pathogenesis, highlighting the interplay of IR, oxidative stress, and inflammatory responses within this intricate framework[38,39]. As ongoing research continues to unveil the nuanced connections between blood traits and systemic health, these findings contribute to a broader understanding of the intricate web of factors influencing metabolic and liver-related disorders.

HGB is the most common component of erythrocytes and is the carrier of carbon dioxide and oxygen through the vascular network to body cells. The intricate relationship between elevated HGB levels and increased risk of NAFLD is underscored by various physiological mechanisms. Elevated HGB not only is positively correlated with NAFLD risk but also serves as a diagnostic indicator for disease progression[39-41]. The repercussions of increased HGB include increased blood viscosity, compromised hepatic blood flow perfusion, and impaired microcirculation, culminating in hepatocyte ischemia and hypoxia. Furthermore, the cascade of events includes hypoxia-induced oxidative stress, disruptions in hepatic glycogen deposition, and diminished insulin sensitivity. This complex interplay also involves the upregulation of hepatic lipid synthesis genes and the downregulation of lipid metabolism genes[33,42]. These molecular and physiological alterations collectively contribute to increased susceptibility to NAFLD. Additionally, the robustness of these findings is supported by MR analysis, which establishes a causal relationship between genetically predisposed HGB levels and the levels of four liver enzymes, as well as the incidence of NAFLD. Importantly, even after adjusting for confounding factors such as the WHR and T2D status in multivariable MR analyses, the persistent causal association underscores the critical role of HGB in the development and progression of NAFLD and its impact on liver health.

RET serves as an indicator reflecting the haematopoietic function of bone marrow, drawing considerable attention from scholars worldwide for its applications in diagnosing and treating anaemic conditions, as well as in radiotherapy for patients with tumours. Notably, previous findings revealed marked increases in RET% and RET levels within the chronic hepatitis cohort, suggesting a potential link between RET and liver health[43]. Additionally, other studies have confirmed that RET can indicate liver fibrosis severity to a certain extent, thus serving as a diagnostic marker for liver fibrosis and its routine monitoring[44]. Moreover, anaemia resulting from malabsorption of iron, folic acid, and vitamin B12 in patients with CLDs may present as elevated RET levels[45]. Expanding on these observations, our MR study adds a genetic perspective, indicating that genetically predicted higher RET% levels increase the risk of NAFLD. This aligns with findings from independent datasets, collectively reinforcing the validity of the conclusion and providing robust genetic support for previously observed associations. The convergence of evidence from various sources underscores the multifaceted role of RET in liver health and positions it as a valuable marker for both haematopoietic function and liver-related conditions.

A key advantage of this research is its use of the MR approach, which effectively mitigates the impact of confounding factors and the issue of reverse causality typically encountered in observational research. This method provides a thorough examination of the causal links between blood cell trait circulation and the levels of liver enzymes, as well as the risk of NAFLD. In addition, we used data from an independent GWAS in NAFLD to validate our findings in the discovery data and combined causal effect estimates from both datasets through meta-analysis to increase statistical power and improve estimation accuracy. The associations remained consistent in the sensitivity analyses, and no indication of unbalanced pleiotropy was detected. Furthermore, we performed MVMR analyses for traits with strong phenotypes, and the adjusted associations remained substantially stable.

Interpreting the results of our MR study requires careful consideration of several limitations. First, MR provides only a preliminary assessment of the causality between exposure and disease, without delving into the specific biological pathways that underpin these relationships. Our study acknowledges the potential for residual confounding factors that may not have been identified or documented in the current literature. Additionally, MR studies do not offer individual-level data, which limits the ability to examine potential nonlinear relationships. Consequently, robust individual-level data are essential to better understand the impact of elevated blood cell counts on the development of NAFLD.

Finally, the findings from this MR study are grounded in GWAS summary statistics from the European population. However, the generalizability of these results to other ethnic groups remains an open question that necessitates further investigation. To address this, cross-ethnic group studies should be undertaken. These studies compare genetic relationships with NAFLD across different populations, aiming to identify any disparities in the gene-NAFLD association. Expanding the research to integrate multiomics data encompassing transcriptomics and proteomics with clinical data from a variety of ethnic backgrounds can deepen our comprehension of the complex gene-NAFLD interplay. Incorporating MR analysis within this framework is advantageous, as it employs genetic variants as IVs. This approach offers robust evidence for the causal relationship between blood traits and NAFLD, enhancing our grasp of the underlying mechanisms involved.

CONCLUSION

Taking into account both our MR and MVMR results, the associations between high HGB, HCT, and RET% with liver injury and the risk of NAFLD may act independently. These findings have clinical implications, as they suggest the future potential for evaluating blood cell traits as targets for liver injury and NAFLD prevention or treatment.

ACKNOWLEDGEMENTS

The authors acknowledge the researchers of the original studies for sharing the GWAS data used in this project.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Gastroenterology and hepatology

Country of origin: China

Peer-review report’s classification

Scientific Quality: Grade B

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade B

P-Reviewer: Moriyama K S-Editor: Li L L-Editor: A P-Editor: Che XX
==== Refs
1 Asrani SK Devarbhavi H Eaton J Kamath PS Burden of liver diseases in the world J Hepatol 2019 70 151 171 30266282
2 Samanta A Sen Sarma M Metabolic dysfunction-associated steatotic liver disease: A silent pandemic World J Hepatol 2024 16 511 516 38689742
3 Samuel VT Shulman GI Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases Cell Metab 2018 27 22 41 28867301
4 En Li Cho E Ang CZ Quek J Fu CE Lim LKE Heng ZEQ Tan DJH Lim WH Yong JN Zeng R Chee D Nah B Lesmana CRA Bwa AH Win KM Faulkner C Aboona MB Lim MC Syn N Kulkarni AV Suzuki H Takahashi H Tamaki N Wijarnpreecha K Huang DQ Muthiah M Ng CH Loomba R Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis Gut 2023 72 2138 2148 37491159
5 Vargas M Cardoso Toniasso SC Riedel PG Baldin CP Dos Reis FL Pereira RM Brum MCB Joveleviths D Alvares-da-Silva MR Metabolic disease and the liver: A review World J Hepatol 2024 16 33 40 38313243
6 Xie J Huang H Liu Z Li Y Yu C Xu L Xu C The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study Hepatology 2023 77 949 964 35971878
7 Newton KP Lavine JE Wilson L Behling C Vos MB Molleston JP Rosenthal P Miloh T Fishbein MH Jain AK Murray KF Schwimmer JB Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis Hepatology 2021 73 937 951 32416645
8 Costa G Kouskoff V Lacaud G Origin of blood cells and HSC production in the embryo Trends Immunol 2012 33 215 223 22365572
9 Chen MH Raffield LM Mousas A Sakaue S Huffman JE Moscati A Trivedi B Jiang T Akbari P Vuckovic D Bao EL Zhong X Manansala R Laplante V Chen M Lo KS Qian H Lareau CA Beaudoin M Hunt KA Akiyama M Bartz TM Ben-Shlomo Y Beswick A Bork-Jensen J Bottinger EP Brody JA van Rooij FJA Chitrala K Cho K Choquet H Correa A Danesh J Di Angelantonio E Dimou N Ding J Elliott P Esko T Evans MK Floyd JS Broer L Grarup N Guo MH Greinacher A Haessler J Hansen T Howson JMM Huang QQ Huang W Jorgenson E Kacprowski T Kähönen M Kamatani Y Kanai M Karthikeyan S Koskeridis F Lange LA Lehtimäki T Lerch MM Linneberg A Liu Y Lyytikäinen LP Manichaikul A Martin HC Matsuda K Mohlke KL Mononen N Murakami Y Nadkarni GN Nauck M Nikus K Ouwehand WH Pankratz N Pedersen O Preuss M Psaty BM Raitakari OT Roberts DJ Rich SS Rodriguez BAT Rosen JD Rotter JI Schubert P Spracklen CN Surendran P Tang H Tardif JC Trembath RC Ghanbari M Völker U Völzke H Watkins NA Zonderman AB VA Million Veteran Program, Wilson PWF, Li Y, Butterworth AS, Gauchat JF, Chiang CWK, Li B, Loos RJF, Astle WJ, Evangelou E, van Heel DA, Sankaran VG, Okada Y, Soranzo N, Johnson AD, Reiner AP, Auer PL, Lettre G Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations Cell 2020 182 1198 1213.e14 32888493
10 Vuckovic D Bao EL Akbari P Lareau CA Mousas A Jiang T Chen MH Raffield LM Tardaguila M Huffman JE Ritchie SC Megy K Ponstingl H Penkett CJ Albers PK Wigdor EM Sakaue S Moscati A Manansala R Lo KS Qian H Akiyama M Bartz TM Ben-Shlomo Y Beswick A Bork-Jensen J Bottinger EP Brody JA van Rooij FJA Chitrala KN Wilson PWF Choquet H Danesh J Di Angelantonio E Dimou N Ding J Elliott P Esko T Evans MK Felix SB Floyd JS Broer L Grarup N Guo MH Guo Q Greinacher A Haessler J Hansen T Howson JMM Huang W Jorgenson E Kacprowski T Kähönen M Kamatani Y Kanai M Karthikeyan S Koskeridis F Lange LA Lehtimäki T Linneberg A Liu Y Lyytikäinen LP Manichaikul A Matsuda K Mohlke KL Mononen N Murakami Y Nadkarni GN Nikus K Pankratz N Pedersen O Preuss M Psaty BM Raitakari OT Rich SS Rodriguez BAT Rosen JD Rotter JI Schubert P Spracklen CN Surendran P Tang H Tardif JC Ghanbari M Völker U Völzke H Watkins NA Weiss S VA Million Veteran Program, Cai N, Kundu K, Watt SB, Walter K, Zonderman AB, Cho K, Li Y, Loos RJF, Knight JC, Georges M, Stegle O, Evangelou E, Okada Y, Roberts DJ, Inouye M, Johnson AD, Auer PL, Astle WJ, Reiner AP, Butterworth AS, Ouwehand WH, Lettre G, Sankaran VG, Soranzo N The Polygenic and Monogenic Basis of Blood Traits and Diseases Cell 2020 182 1214 1231.e11 32888494
11 Skrivankova VW Richmond RC Woolf BAR Yarmolinsky J Davies NM Swanson SA VanderWeele TJ Higgins JPT Timpson NJ Dimou N Langenberg C Golub RM Loder EW Gallo V Tybjaerg-Hansen A Davey Smith G Egger M Richards JB Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement JAMA 2021 326 1614 1621 34698778
12 Pazoki R Vujkovic M Elliott J Evangelou E Gill D Ghanbari M van der Most PJ Pinto RC Wielscher M Farlik M Zuber V de Knegt RJ Snieder H Uitterlinden AG Lifelines Cohort Study, Lynch JA, Jiang X, Said S, Kaplan DE, Lee KM, Serper M, Carr RM, Tsao PS, Atkinson SR, Dehghan A, Tzoulaki I, Ikram MA, Herzig KH, Järvelin MR, Alizadeh BZ, O'Donnell CJ, Saleheen D, Voight BF, Chang KM, Thursz MR, Elliott P VA Million Veteran Program Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes Nat Commun 2021 12 2579 33972514
13 Ward LD Tu HC Quenneville CB Tsour S Flynn-Carroll AO Parker MM Deaton AM Haslett PAJ Lotta LA Verweij N Ferreira MAR Regeneron Genetics Center Geisinger-Regeneron DiscovEHR Collaboration, Baras A, Hinkle G, Nioi P GWAS of serum ALT and AST reveals an association of SLC30A10 Thr95Ile with hypermanganesemia symptoms Nat Commun 2021 12 4571 34315874
14 Emdin CA Khera AV Kathiresan S Mendelian Randomization JAMA 2017 318 1925 1926 29164242
15 Ghodsian N Abner E Emdin CA Gobeil É Taba N Haas ME Perrot N Manikpurage HD Gagnon É Bourgault J St-Amand A Couture C Mitchell PL Bossé Y Mathieu P Vohl MC Tchernof A Thériault S Khera AV Esko T Arsenault BJ Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease Cell Rep Med 2021 2 100437 34841290
16 Hemani G Zheng J Elsworth B Wade KH Haberland V Baird D Laurin C Burgess S Bowden J Langdon R Tan VY Yarmolinsky J Shihab HA Timpson NJ Evans DM Relton C Martin RM Davey Smith G Gaunt TR Haycock PC The MR-Base platform supports systematic causal inference across the human phenome Elife 2018 7
17 Bowden J Del Greco M F Minelli C Zhao Q Lawlor DA Sheehan NA Thompson J Davey Smith G Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption Int J Epidemiol 2019 48 728 742 30561657
18 Burgess S Scott RA Timpson NJ Davey Smith G Thompson SG EPIC- InterAct Consortium Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors Eur J Epidemiol 2015 30 543 552 25773750
19 Bowden J Davey Smith G Burgess S Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression Int J Epidemiol 2015 44 512 525 26050253
20 Bowden J Davey Smith G Haycock PC Burgess S Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator Genet Epidemiol 2016 40 304 314 27061298
21 Hartwig FP Davey Smith G Bowden J Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption Int J Epidemiol 2017 46 1985 1998 29040600
22 Bowden J Spiller W Del Greco M F Sheehan N Thompson J Minelli C Davey Smith G Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression Int J Epidemiol 2018 47 1264 1278 29961852
23 Verbanck M Chen CY Neale B Do R Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases Nat Genet 2018 50 693 698 29686387
24 Burgess S Thompson SG Interpreting findings from Mendelian randomization using the MR-Egger method Eur J Epidemiol 2017 32 377 389 28527048
25 Greco M FD Minelli C Sheehan NA Thompson JR Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome Stat Med 2015 34 2926 2940 25950993
26 Burgess S Bowden J Fall T Ingelsson E Thompson SG Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants Epidemiology 2017 28 30 42 27749700
27 Pulit SL Stoneman C Morris AP Wood AR Glastonbury CA Tyrrell J Yengo L Ferreira T Marouli E Ji Y Yang J Jones S Beaumont R Croteau-Chonka DC Winkler TW GIANT Consortium, Hattersley AT, Loos RJF, Hirschhorn JN, Visscher PM, Frayling TM, Yaghootkar H, Lindgren CM Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry Hum Mol Genet 2019 28 166 174 30239722
28 Mahajan A Spracklen CN Zhang W Ng MCY Petty LE Kitajima H Yu GZ Rüeger S Speidel L Kim YJ Horikoshi M Mercader JM Taliun D Moon S Kwak SH Robertson NR Rayner NW Loh M Kim BJ Chiou J Miguel-Escalada I Della Briotta Parolo P Lin K Bragg F Preuss MH Takeuchi F Nano J Guo X Lamri A Nakatochi M Scott RA Lee JJ Huerta-Chagoya A Graff M Chai JF Parra EJ Yao J Bielak LF Tabara Y Hai Y Steinthorsdottir V Cook JP Kals M Grarup N Schmidt EM Pan I Sofer T Wuttke M Sarnowski C Gieger C Nousome D Trompet S Long J Sun M Tong L Chen WM Ahmad M Noordam R Lim VJY Tam CHT Joo YY Chen CH Raffield LM Lecoeur C Prins BP Nicolas A Yanek LR Chen G Jensen RA Tajuddin S Kabagambe EK An P Xiang AH Choi HS Cade BE Tan J Flanagan J Abaitua F Adair LS Adeyemo A Aguilar-Salinas CA Akiyama M Anand SS Bertoni A Bian Z Bork-Jensen J Brandslund I Brody JA Brummett CM Buchanan TA Canouil M Chan JCN Chang LC Chee ML Chen J Chen SH Chen YT Chen Z Chuang LM Cushman M Das SK de Silva HJ Dedoussis G Dimitrov L Doumatey AP Du S Duan Q Eckardt KU Emery LS Evans DS Evans MK Fischer K Floyd JS Ford I Fornage M Franco OH Frayling TM Freedman BI Fuchsberger C Genter P Gerstein HC Giedraitis V González-Villalpando C González-Villalpando ME Goodarzi MO Gordon-Larsen P Gorkin D Gross M Guo Y Hackinger S Han S Hattersley AT Herder C Howard AG Hsueh W Huang M Huang W Hung YJ Hwang MY Hwu CM Ichihara S Ikram MA Ingelsson M Islam MT Isono M Jang HM Jasmine F Jiang G Jonas JB Jørgensen ME Jørgensen T Kamatani Y Kandeel FR Kasturiratne A Katsuya T Kaur V Kawaguchi T Keaton JM Kho AN Khor CC Kibriya MG Kim DH Kohara K Kriebel J Kronenberg F Kuusisto J Läll K Lange LA Lee MS Lee NR Leong A Li L Li Y Li-Gao R Ligthart S Lindgren CM Linneberg A Liu CT Liu J Locke AE Louie T Luan J Luk AO Luo X Lv J Lyssenko V Mamakou V Mani KR Meitinger T Metspalu A Morris AD Nadkarni GN Nadler JL Nalls MA Nayak U Nongmaithem SS Ntalla I Okada Y Orozco L Patel SR Pereira MA Peters A Pirie FJ Porneala B Prasad G Preissl S Rasmussen-Torvik LJ Reiner AP Roden M Rohde R Roll K Sabanayagam C Sander M Sandow K Sattar N Schönherr S Schurmann C Shahriar M Shi J Shin DM Shriner D Smith JA So WY Stančáková A Stilp AM Strauch K Suzuki K Takahashi A Taylor KD Thorand B Thorleifsson G Thorsteinsdottir U Tomlinson B Torres JM Tsai FJ Tuomilehto J Tusie-Luna T Udler MS Valladares-Salgado A van Dam RM van Klinken JB Varma R Vujkovic M Wacher-Rodarte N Wheeler E Whitsel EA Wickremasinghe AR van Dijk KW Witte DR Yajnik CS Yamamoto K Yamauchi T Yengo L Yoon K Yu C Yuan JM Yusuf S Zhang L Zheng W FinnGen eMERGE Consortium, Raffel LJ, Igase M, Ipp E, Redline S, Cho YS, Lind L, Province MA, Hanis CL, Peyser PA, Ingelsson E, Zonderman AB, Psaty BM, Wang YX, Rotimi CN, Becker DM, Matsuda F, Liu Y, Zeggini E, Yokota M, Rich SS, Kooperberg C, Pankow JS, Engert JC, Chen YI, Froguel P, Wilson JG, Sheu WHH, Kardia SLR, Wu JY, Hayes MG, Ma RCW, Wong TY, Groop L, Mook-Kanamori DO, Chandak GR, Collins FS, Bharadwaj D, Paré G, Sale MM, Ahsan H, Motala AA, Shu XO, Park KS, Jukema JW, Cruz M, McKean-Cowdin R, Grallert H, Cheng CY, Bottinger EP, Dehghan A, Tai ES, Dupuis J, Kato N, Laakso M, Köttgen A, Koh WP, Palmer CNA, Liu S, Abecasis G, Kooner JS, Loos RJF, North KE, Haiman CA, Florez JC, Saleheen D, Hansen T, Pedersen O, Mägi R, Langenberg C, Wareham NJ, Maeda S, Kadowaki T, Lee J, Millwood IY, Walters RG, Stefansson K, Myers SR, Ferrer J, Gaulton KJ, Meigs JB, Mohlke KL, Gloyn AL, Bowden DW, Below JE, Chambers JC, Sim X, Boehnke M, Rotter JI, McCarthy MI, Morris AP Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation Nat Genet 2022 54 560 572 35551307
29 Burgess S Thompson SG Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects Am J Epidemiol 2015 181 251 260 25632051
30 Curtin F Schulz P Multiple correlations and Bonferroni's correction Biol Psychiatry 1998 44 775 777 9798082
31 Gyawali P Richards RS Association of altered hemorheology with oxidative stress and inflammation in metabolic syndrome Redox Rep 2015 20 139 144 25494675
32 de Simone G Devereux RB Chien S Alderman MH Atlas SA Laragh JH Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults Circulation 1990 81 107 117 2297818
33 Yu KJ Zhang MJ Li Y Wang RT Increased whole blood viscosity associated with arterial stiffness in patients with non-alcoholic fatty liver disease J Gastroenterol Hepatol 2014 29 540 544 23981121
34 Choi KM Lee J Kim YH Kim KB Kim DL Kim SG Shin DH Kim NH Park IB Choi DS Baik SH Koreans-Southwest Seoul (SWS) Study Relation between insulin resistance and hematological parameters in elderly Koreans-Southwest Seoul (SWS) Study Diabetes Res Clin Pract 2003 60 205 212 12757983
35 Ben-Assayag H Brzezinski RY Berliner S Zeltser D Shapira I Rogowski O Toker S Eldor R Shenhar-Tsarfaty S Transitioning from having no metabolic abnormality nor obesity to metabolic impairment in a cohort of apparently healthy adults Cardiovasc Diabetol 2023 22 226 37633936
36 Lin JD Chiou WK Chang HY Liu FH Weng HF Liu TH Association of hematological factors with components of the metabolic syndrome in older and younger adults Aging Clin Exp Res 2006 18 477 484 17255636
37 Zhong F Guan L Lin H Zhao M Qin Y Li Q Yuan Z Yang G Gao L Zhao J Red Blood Cell Count: An Unrecognized Risk Factor for Nonalcoholic Fatty Liver Disease Front Endocrinol (Lausanne) 2021 12 760981 34950103
38 Tilg H Adolph TE Moschen AR Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade Hepatology 2021 73 833 842 32780879
39 Rosso C Kazankov K Younes R Esmaili S Marietti M Sacco M Carli F Gaggini M Salomone F Møller HJ Abate ML Vilstrup H Gastaldelli A George J Grønbæk H Bugianesi E Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease J Hepatol 2019 71 1012 1021 31301321
40 Chung GE Yim JY Kim D Kwak MS Yang JI Chung SJ Yang SY Kim JS Associations between hemoglobin concentrations and the development of incidental metabolic syndrome or nonalcoholic fatty liver disease Dig Liver Dis 2017 49 57 62 27810399
41 Bennett RW The status of the state-federal tuberculosis eradication program Proc Annu Meet U S Anim Health Assoc 1979 488 497 298936
42 Fiorentino TV Marini MA Succurro E Andreozzi F Sciacqua A Hribal ML Perticone F Sesti G Association between hemoglobin glycation index and hepatic steatosis in non-diabetic individuals Diabetes Res Clin Pract 2017 134 53 61 28993156
43 Huang CF Huang CI Yeh ML Hou C Hou NJ Hsieh MY Huang JF Chen SC Lin ZY Dai CY Chuang WL Yu ML Disease severity and erythropoiesis in chronic hepatitis C J Gastroenterol Hepatol 2017 32 864 869 27637864
44 Parker R Armstrong MJ Bruns T Hodson J Rowe IA Corbett CD Reuken PA Gunson BK Houlihan DD Stephenson B Malessa C Lester W Ferguson JW Reticulocyte count and hemoglobin concentration predict survival in candidates for liver transplantation Transplantation 2014 97 463 469 24531823
45 Brugnara C Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function Crit Rev Clin Lab Sci 2000 37 93 130 10811141
